Genelux Corporation to Participate in a Fireside Chat With H.C. Wainwright
Genelux Corporation to Participate in a Fireside Chat With H.C. Wainwright
WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board will participate in a virtual fireside chat with H.C. Wainwright & Co. on December 16, 2024.
加州西湖村，2024年12月13日 (全球新闻通讯) -- Genelux Corporation (纳斯达克: GNLX)，一家处于晚期临床阶段的免疫肿瘤学公司，今天宣布，董事会主席兼首席执行官托马斯·辛德里克将于2024年12月16日参加与H.C. Wainwright & Co.的虚拟炉边聊天。
Biotech Equity Research Analyst, Emily Bodnar, will moderate the HCW@Home session which is scheduled to begin at 11:00 a.m. ET. The discussion will focus on the company's clinical program of its lead candidate, Olvi-Vec, including its ongoing Phase 3 registration trial in platinum resistant/refractory ovarian cancer (PRROC), Phase 1b/2 trial in small-cell lung cancer (SCLC) and Phase 2 trial in non-small cell lung cancer (NSCLC). To join, please register at . An archived replay will be available for approximately 90 days following the event on the company's IR page.
生物技术股票研究分析师艾米莉·博德纳将主持定于上午11:00（东部时间）开始的HCW@Home会议。讨论将集中在公司的主导候选药物Olvi-Vec的临床项目上，包括其正在进行的铂耐药/难治性卵巢癌（PRROC）的3期注册试验、小细胞肺癌（SCLC）的1b/2期试验以及非小细胞肺癌（NSCLC）的2期试验。要加入，请注册。活动结束后，档案重播将在公司的投资者关系页面上提供，持续大约90天。
About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux's discovery and development efforts revolves around its proprietary CHOICE platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit and follow us on Twitter @Genelux_Corp and on LinkedIn.
关于Genelux Corporation
Genelux是一家处于晚期临床阶段的生物制药公司，专注于开发针对患有侵袭性和/或难治性实体瘤的患者的下一代溶瘤免疫疗法。公司的最先进产品候选药物Olvi-Vec（olvimulogene nanivacirepvec）是一种专有的、改造的牛痘病毒株。Olvi-Vec目前正在OnPrime/GOG-3076中接受评估，这是一个多中心、随机、开放标签的3期注册试验，评估Olvi-Vec与铂基双药+贝伐单抗联合治疗与医生选择化疗和贝伐单抗在铂耐药/难治性卵巢癌患者中的疗效和安全性。Genelux的发现和开发工作的核心围绕其专有的CHOICE平台，该平台使得公司开发出丰富的隔离和工程改造的溶瘤牛痘病毒免疫治疗产品候选药物，包括Olvi-Vec。有关更多信息，请访问并在Twitter上关注我们 @Genelux_Corp 和LinkedIn。
Investor and Media Contacts
投资者和媒体联系人
Ankit Bhargava, MD
Allele Communications, LLC
genelux@allelecomms.com
安基特·巴尔加瓦，医学博士
Allele Communications, LLC
genelux@allelecomms.com
Source: Genelux Corporation
来源：Genelux公司
Source: Genelux Corporation
来源：Genelux公司